Table 5.

Statistical analysis comparing the GNP-TKI versus TKI

Source of variation	Total variation (%)	P-value	P-value summary	Significant?
GNP-lestaurtinib, days 1–14
OCI-AML3
Interaction	39.61	<0.0001	****	Yes
Row factor	33.10	<0.0001	****	Yes
Column factor	26.77	<0.0001	****	Yes
GNP-sorafenib, days 1–14
OCI-AML3
Interaction	39.06	<0.0001	****	Yes
Row factor	29.22	<0.0001	****	Yes
Column factor	25.70	<0.0001	****	Yes
GNP-quizartinib, days 1–14
OCI-AML3
Interaction	38.53	<0.0001	****	Yes
Row factor	29.31	<0.0001	****	Yes
Column factor	25.25	<0.0001	****	Yes
GNP-lestaurtinib, days 1–14
THP1
Interaction	38.72	<0.0001	****	Yes
Row factor	29.99	<0.0001	****	Yes
Column factor	25.55	<0.0001	****	Yes
GNP-sorafenib, days 1–14
THP1
Interaction	38.61	<0.0001	****	Yes
Row factor	30.84	<0.0001	****	Yes
Column factor	25.37	<0.0001	****	Yes
GNP-quizartinib, days 1–14
THP1
Interaction	37.63	<0.0001	****	Yes
Row factor	31.59	<0.0001	****	Yes
Column factor	25.44	<0.0001	****	Yes

Note:

^****Statistically significant.

Abbreviations: GNP, gold nanoparticle; TKI, tyrosine kinase inhibitor.